Abiopharma

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Exact Sciences Announces Second Quarter 2025 Results

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Talkspace to Participate in Upcoming Investor Conference

HilleVax Reports Second Quarter 2025 Financial Results

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance